Towards Healthcare
Point of Care Infectious Disease Testing Market to Lead USD 17.75 Bn by 2034

Point of Care Infectious Disease Testing Market Latest Growth Insights

Projections indicate that, point-of-care infectious disease testing industry is projected to rise from USD 11.9 billion in 2024 to USD 17.75 billion by 2034, reflecting a CAGR of 4.34% over the next decade. The point-of-care infectious disease testing market is expanding due to patient-centric care as well as increasing lateral flow test innovations. North America led the market due to the presence of the advanced healthcare sector.

  • Insight Code: 6167
  • No. of Pages: 150+
  • Format: PDF/PPT/Excel
  • Published: September 2025
  • Report Covered: [Revenue + Volume]
  • Historical Year: 2021-2022
  • Base Year: 2023
  • Estimated Years: 2024-2033

About The Author

Deepa Pandey is a focused and detail-oriented market research professional with growing expertise in the healthcare sector, delivering high-quality insights across therapeutic areas, diagnostics, biotechnology, and healthcare services.

She began her research career at Precedence Research, where she contributed to a wide range of healthcare industry studies, helping build a strong foundation in market intelligence and strategic research. Currently, Deepa plays a critical role at Towards Healthcare, while also extending her research capabilities across Statifacts, supporting cross-industry intelligence initiatives with a focus on healthcare.

Her ability to distill complexity into clarity has made her a trusted contributor to both internal teams and external clients across the healthcare value chain. By combining professionalism with an evolving depth in healthcare research, Deepa consistently adds value to projects that demand critical thinking, market precision, and industry-specific knowledge. Her contributions help organizations navigate the complexities of regulated markets and make data-backed growth decisions.

FAQ's

The point-of-care infectious disease testing market in 2025 is valued at USD 12.42 billion and is projected to climb to USD 17.75 billion by 2034, with a CAGR of 4.34% over the forecast period.

North America is currently leading the point-of-care infectious disease testing market due to the presence of the advanced healthcare sector.

The point of care infectious disease testing market includes four segments such as by technology, by disease, by end use, and by region.

Some key players include F. Hoffmann-La Roche Ltd, Abbott, Siemens Healthineers, and Thermo Fisher Scientific Inc.

The point-of-care infectious disease testing helps in the diagnosis of infectious diseases in resource-limited areas, as well as in remote areas.

Ministry of Health and Family Welfare, Government of India, National Institutes of Health, FDA, WHO, PIB, CDC.